142 related articles for article (PubMed ID: 30322325)
1. Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.
Bhangoo MS; Saven A
Leuk Lymphoma; 2019 May; 60(5):1331-1333. PubMed ID: 30322325
[No Abstract] [Full Text] [Related]
2. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation.
Peyrade F; Re D; Ginet C; Gastaud L; Allegra M; Ballotti R; Thyss A; Zenz T; Auberger P; Robert G
Haematologica; 2013 Feb; 98(2):e20-2. PubMed ID: 23300174
[No Abstract] [Full Text] [Related]
3. Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib.
Shenoi DP; Andritsos LA; Blachly JS; Rogers KA; Moran ME; Anghelina M; Jones JA; Grever MR
Blood Adv; 2019 Jan; 3(2):116-118. PubMed ID: 30630817
[TBL] [Abstract][Full Text] [Related]
4. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
Yiğit Kaya S; Mutlu YG; Malkan ÜY; Mehtap Ö; Keklik Karadağ F; Korkmaz G; Elverdi T; Saydam G; Özet G; Ar MC; Melek E; Maral S; Kaynar L; Sevindik ÖG
Leuk Res; 2024 May; 140():107495. PubMed ID: 38599153
[TBL] [Abstract][Full Text] [Related]
5. BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials.
Liebers N; Roider T; Bohn JP; Haberbosch I; Pircher A; Ferstl B; Ebnöther M; Wendtner CM; Dearden C; Follows GA; Ho AD; Müller-Tidow C; Dreger P; Troussard X; Zenz T; Dietrich S
Leukemia; 2020 May; 34(5):1454-1457. PubMed ID: 31740808
[No Abstract] [Full Text] [Related]
6. BRAF in the cross-hairs.
Geyer MB; Abdel-Wahab O; Tallman MS
Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib for relapsed or refractory hairy-cell leukaemia.
Baker H
Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26387749
[No Abstract] [Full Text] [Related]
8. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Falini B; De Carolis L; Tiacci E
Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib-induced plantar hyperkeratosis.
Bashline BR; Bedocs PM
Cutis; 2018 Sep; 102(3):E19-E21. PubMed ID: 30372722
[No Abstract] [Full Text] [Related]
10. BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases.
Shin SY; Lee ST; Kim HJ; Ki CS; Jung CW; Kim JW; Kim SH
Ann Lab Med; 2015 Mar; 35(2):257-9. PubMed ID: 25729732
[No Abstract] [Full Text] [Related]
11. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Tiacci E; De Carolis L; Simonetti E; Capponi M; Ambrosetti A; Lucia E; Antolino A; Pulsoni A; Ferrari S; Zinzani PL; Ascani S; Perriello VM; Rigacci L; Gaidano G; Della Seta R; Frattarelli N; Falcucci P; Foà R; Visani G; Zaja F; Falini B
N Engl J Med; 2021 May; 384(19):1810-1823. PubMed ID: 33979489
[TBL] [Abstract][Full Text] [Related]
12. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation.
Munoz J; Schlette E; Kurzrock R
J Clin Oncol; 2013 Jul; 31(20):e351-2. PubMed ID: 23733763
[No Abstract] [Full Text] [Related]
13. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
Handa S; Lee JO; Derkach A; Stone RM; Saven A; Altman JK; Grever MR; Rai KR; Shukla M; Vemuri S; Montoya S; Taylor J; Abdel-Wahab O; Tallman MS; Park JH
Blood; 2022 Dec; 140(25):2663-2671. PubMed ID: 35930750
[TBL] [Abstract][Full Text] [Related]
14. Inhibitor of BRAF
Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
[TBL] [Abstract][Full Text] [Related]
15. Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.
Jones JA; Kraut EH; Deam D; Byrd JC; Grever MR
Leuk Lymphoma; 2012 Mar; 53(3):490-1. PubMed ID: 22165992
[No Abstract] [Full Text] [Related]
16. BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis.
Singh AG; Tchanque-Fossuo CN; Elwood H; Durkin JR
Dermatol Online J; 2020 Feb; 26(2):. PubMed ID: 32239892
[TBL] [Abstract][Full Text] [Related]
17. Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.
Filanovsky K; Yacobi R; Vorst E; Barshack I; Ustaev E; Feldberg E; Shvidel L
Leuk Lymphoma; 2015 Mar; 56(3):823-5. PubMed ID: 25029639
[No Abstract] [Full Text] [Related]
18. Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia.
Chung SY; Shen JG; Ghiuzeli CM
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32928833
[TBL] [Abstract][Full Text] [Related]
19. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis.
Maurer H; Haas P; Wengenmayer T; Lübbert M; Duyster J; Zeiser R
Ann Hematol; 2014 Aug; 93(8):1439-40. PubMed ID: 24337488
[No Abstract] [Full Text] [Related]
20. Efficacy of vemurafenib in hairy-cell leukemia.
Samuel J; Macip S; Dyer MJ
N Engl J Med; 2014 Jan; 370(3):286-8. PubMed ID: 24428489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
